Table 3 Skin response according to history of papules, plaques or tumors.

From: Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

 

N (%)

No history of PPT (TCM), N (%)

History of PPT (TRM/TMM), N (%)

Skin response

CR

17 (44.7)

8 (72.7)

9 (33.3)

PR

8 (21.1)

3 (27.3)

5 (18.5)

SD

9 (23.7)

0

9 (33.3)

PD

4 (10.5)

0

4 (14.8)

Back to article page